I think the next generation Abbvie product will produce better results for Enta but I'm not so sure that Abbvie's market share won't be eroded by new entries.
Huh? ABBV never projected anything close to 6B annual sales for Vpak. Original guidance was 3B which is possible but very unlikely to be met in 2015. This is already priced in.
Market Data 
Markets 
AI
